Second primary malignancy in myelofibrosis patients treated with ruxolitinib. Polverelli N, Elli EM, Abruzzese E, Palumbo GA, et al. Br J Haematol 2021;193:356-368.

Read + Share

Amedeo Smart

Independent Medical Education

Read + Share

Polverelli N, Elli EM, Abruzzese E, Palumbo GA, et al. Second primary malignancy in myelofibrosis patients treated with ruxolitinib. Br J Haematol 2021;193:356-368.
PMID: 33222197